This is an open-label, repeat-dose, Phase 2 study of nedosiran in participants 11 years of age or younger who have PH1, PH2 or PH 3 and relatively intact renal function.~Following the up-to-35- day screening period, participants will return to the clinic for monthly dosing visits through Day 180.~The total duration of this study is approximately 15 months from first participant, first visit, until last participant, last visit.
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.